Added to YB: 2025-01-07
Pitch date: 2024-11-11
ACE.ST [bullish]
Ascelia Pharma AB (publ)
+10.94%
current return
Author Info
SmallPharma shares investment research in Micro & Small Caps with clear catalyst, mainly small pharma after phase II & III. Sign up for the newsletter.
Company Info
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions.
Market Cap
SEK 303.2M
Pitch Price
SEK 2.65
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.15
P/E
-1.93
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Ascelia Pharma - multibagger in the making
ACE.ST: Orviglance MRI agent for kidney-impaired patients post-successful Phase III. 800M USD global market, no competitors in niche. FDA submission mid-2025. 24M USD market cap (7.5M cash) vs. potential 10x M&A value. Risks: commercialization deal terms, regulatory timeline.
Read full article (33 min)